|
Adenoma
|
0.080 |
GeneticVariation
|
group |
BEFREE |
Subjects in both the upper tertiles of NAT2 activity and HAA intake were at increased risk of adenoma compared with subjects in the lower tertiles of NAT2 activity and exposure (2-amino-3,4,8-dimethylimidazo[4,5-f]quinoxaline intake OR 1.70, 95% CI I 1.06 to 2.75; 2-amino-3,8-dimethylimidazo[4,5-f]quinoxaline intake OR 1.91, 95% CI 1.16 to 3.16; and 2-amino-1-methyl-6-phenylimidazo[4,5-b]pyridine intake OR 2.14, 95% CI 1.31 to 3.49).
|
22628494 |
2013 |
|
Adenoma
|
0.080 |
GeneticVariation
|
group |
BEFREE |
In the Prostate, Lung, Colorectal and Ovarian (PLCO) cancer screening trial, we compared NAT1 and NAT2 gene variant distributions for 772 cases with left-sided advanced adenoma and 777 gender and age-matched controls.
|
16981843 |
2006 |
|
Adenoma
|
0.080 |
GeneticVariation
|
group |
BEFREE |
Only the combination of NAT2 slow acetylation and frequent meat consumption (> 5x/week) slightly increased adenoma risk (OR 1.6, 95% CI 1.1-2.3).
|
15090717 |
2004 |
|
Adenoma
|
0.080 |
Biomarker
|
group |
LHGDN |
Combinations of SULT1A1 fast sulfation (*1/*1) and of NAT2 slow acetylation with smoking resulted in a 4 times higher risk of adenomas compared to never smokers with other inherited gene variants, although there was no statistically significant effect modification.
|
14618622 |
2004 |
|
Adenoma
|
0.080 |
GeneticVariation
|
group |
BEFREE |
Combinations of SULT1A1 fast sulfation (*1/*1) and of NAT2 slow acetylation with smoking resulted in a 4 times higher risk of adenomas compared to never smokers with other inherited gene variants, although there was no statistically significant effect modification.
|
14618622 |
2004 |
|
Adenoma
|
0.080 |
GeneticVariation
|
group |
BEFREE |
In contrast, NAT2 genotype and CYP1A2 and NAT2 hepatic activity measured by caffeine urinary metabolites were not associated with adenoma risk, although an increase in risk with rapid CYP1A2 activity could not be ruled out (OR = 1.46; 95% CI 0.76-2.81).
|
11875368 |
2002 |
|
Adenoma
|
0.080 |
Biomarker
|
group |
BEFREE |
Never-smokers showed no variation in risk across acetylator status for either species of polyp, whereas current smokers showed ORs of 2.0 (1.2-3.2) and 2.3 (1.4-3.9) for adenomas and 3.9 (2.1-7.1) and 4.9 (2.6-9.4) for hyperplastic polyps for slow and intermediate/fast NAT2, respectively, compared with slow-NAT2 never-smokers.
|
9950242 |
1999 |
|
Adenoma
|
0.080 |
GeneticVariation
|
group |
BEFREE |
When combined with our data on the NAT2 acetylation polymorphism, we saw no evidence for an association between N-acetyltransferases and prevalence of adenomas.
|
9682272 |
1998 |
|
Adenoma
|
0.080 |
GeneticVariation
|
group |
BEFREE |
We found neither an increased adenoma prevalence in subjects homozygous or heterozygous for the NAT1*10 fast acetylator allele (odds ratio 1.04; 95% confidence interval 0.79-1.36), nor a gene-gene interaction between NA1 and NAT2 (P(interaction) = 0.59).
|
8895478 |
1996 |